All Drug Development articles – Page 7
-
NewsAI model demonstrates potential for streamlining clinical trials
The novel AI-led approach could accelerate development of Alzheimer’s treatments by reducing related costs.
-
NewsUK Government publishes Life Sciences Sector Plan
While a focus on accelerating access for innovative medicines has been welcomed, industry representatives caution that current system infrastructure could hinder the plans proposed by the UK Government.
-
NewsNICE recommends innovative cystic fibrosis therapy
Recommendation of the once-daily triple therapy increases the number of eligible cystic fibrosis patients who can access treatments in the UK.
-
NewsUpdated licensing agreement marks “major milestone” in global HIV response
The expanded agreement between ViiV Healthcare and Medicines Patent Pool (MPP) provides a more patient-centric treatment approach for HIV patients worldwide.
-
NewsTechnology advancement to drive lab automation market through next decade
While high costs are hindering growth in the lab automation market, research highlights that new innovations like AI offer potential to expand this rapidly evolving industry.
-
ArticleAdvancing endotoxin testing with sustainable recombinant LAL solutions
Fujifilm Wako discusses its Pyrostar™ Neo+ reagent and reveals how recombinant technology is transforming endotoxin testing while addressing evolving industry demands.
-
NewsMSD acquisition to accelerate first-in-class COPD drug
The $10 billion acquisition involves advancement of a novel inhaled therapy which has potential to redefine standard of care in respiratory disease.
-
NewsRealising safer tuberculosis treatment with novel antibiotics
Based on the clinical trial results, the drugs could particularly benefit tuberculosis patients requiring extended therapeutic intervention.
-
ArticleSupporting the pharmaceutical industry – how a CDMO can help
After their recent webinar, European Pharmaceutical Review’s Head of Content Ian Betteridge spoke with the team at Adragos Pharma to discuss the role of a CDMO and their importance in the fill and finish sector.
-
NewsNew Amgen data highlights promise in gastric cancer
The top-line Phase III findings illustrate potential of the monoclonal antibody plus chemotherapy as a first-line gastric cancer treatment.
-
NewsFDA approves first-of-a-kind oral therapy for rare disease
The US drug agency’s authorisation provides hereditary angioedema (HAE) patients with the first new on-demand treatment in over ten years.
-
NewsNext drug patent cliff to challenge Big Pharma strategy
While the pharmaceutical market is expected to witness strong pricing competition, there is also significant opportunity for biotech companies, research says.
-
NewsGene therapy could improve genetic deafness
The study represents the first time the injectable gene therapy has been evaluated in teenagers and adults.
-
NewsNovel pre-filled autoinjector receives EU approval
The EU authorisation offers a new treatment option for acromegaly, providing effective disease control and enabling convenient self-administration.
-
NewsAbbVie immunology deal to advance potential first-in-class therapy
The new acquisition, worth up to $2.1 billion, gives AbbVie rights to a potential first-in-class drug for B cell-mediated autoimmune diseases.
-
ArticleAlliance for impact - advancing CGT development in Europe
Cell therapy expert Lindsay Davies, PhD, FHEA, discusses the key considerations for moving the needle to broader adoption of CGTs in Europe.
-
NewsGilead partners to advance novel oral oncology drug
The deal between Gilead Sciences and Kymera Therapeutics could lead to development of safer and more effective cancer treatments.
-
WebinarLipid formulations in softgels - enhancing bioavailability and therapeutic efficacy
This webinar will explore how lipid formulations in softgels can enhance drug absorption and bioavailability.
-
NewsRadioligand therapy could address multiple cancer types
The investigational dual-targeting treatment provided strong and durable delivery to tumours, allowing for a high dose of targeted radiation, early results show.
-
ReportStreamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs).